These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23668934)

  • 1. The zebrafish as a model to study polycystic liver disease.
    Tietz Bogert PS; Huang BQ; Gradilone SA; Masyuk TV; Moulder GL; Ekker SC; Larusso NF
    Zebrafish; 2013 Jun; 10(2):211-7. PubMed ID: 23668934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
    Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
    J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.
    Cornec-Le Gall E; Torres VE; Harris PC
    J Am Soc Nephrol; 2018 Jan; 29(1):13-23. PubMed ID: 29038287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver cyst gene knockout in cholangiocytes inhibits cilium formation and Wnt signaling.
    Wills ES; Te Morsche RHM; van Reeuwijk J; Horn N; Geomini I; van de Laarschot LFM; Mans DA; Ueffing M; Boldt K; Drenth JPH; Roepman R
    Hum Mol Genet; 2017 Nov; 26(21):4190-4202. PubMed ID: 28973524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.
    Fedeles SV; Tian X; Gallagher AR; Mitobe M; Nishio S; Lee SH; Cai Y; Geng L; Crews CM; Somlo S
    Nat Genet; 2011 Jun; 43(7):639-47. PubMed ID: 21685914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cystic liver diseases. Genetics and cell biology].
    Housset C
    Gastroenterol Clin Biol; 2005; 29(8-9):861-9. PubMed ID: 16294159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
    Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
    Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes.
    Wills ES; Cnossen WR; Veltman JA; Woestenenk R; Steehouwer M; Salomon J; Te Morsche RH; Huch M; Hehir-Kwa JY; Banning MJ; Pfundt R; Roepman R; Hoischen A; Drenth JP
    Eur J Hum Genet; 2016 Dec; 24(12):1707-1714. PubMed ID: 27552964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
    Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
    Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic second-hit mutations leads to polycystic liver diseases.
    Banales JM; Munoz-Garrido P; Bujanda L
    World J Gastroenterol; 2013 Jan; 19(1):141-3. PubMed ID: 23326178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated polycystic liver disease genes define effectors of polycystin-1 function.
    Besse W; Dong K; Choi J; Punia S; Fedeles SV; Choi M; Gallagher AR; Huang EB; Gulati A; Knight J; Mane S; Tahvanainen E; Tahvanainen P; Sanna-Cherchi S; Lifton RP; Watnick T; Pei YP; Torres VE; Somlo S
    J Clin Invest; 2017 May; 127(5):1772-1785. PubMed ID: 28375157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation.
    Gao H; Wang Y; Wegierski T; Skouloudaki K; Pütz M; Fu X; Engel C; Boehlke C; Peng H; Kuehn EW; Kim E; Kramer-Zucker A; Walz G
    Hum Mol Genet; 2010 Jan; 19(1):16-24. PubMed ID: 19801576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.
    Chebib FT; Jung Y; Heyer CM; Irazabal MV; Hogan MC; Harris PC; Torres VE; El-Zoghby ZM
    Nephrol Dial Transplant; 2016 Jun; 31(6):952-60. PubMed ID: 26932689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sec63 and Xbp1 regulate IRE1α activity and polycystic disease severity.
    Fedeles SV; So JS; Shrikhande A; Lee SH; Gallagher AR; Barkauskas CE; Somlo S; Lee AH
    J Clin Invest; 2015 May; 125(5):1955-67. PubMed ID: 25844898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
    Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
    Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
    United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
    Amura CR; Brodsky KS; Groff R; Gattone VH; Voelkel NF; Doctor RB
    Am J Physiol Cell Physiol; 2007 Jul; 293(1):C419-28. PubMed ID: 17475663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease.
    Janssen MJ; Waanders E; Te Morsche RH; Xing R; Dijkman HB; Woudenberg J; Drenth JP
    Gastroenterology; 2011 Dec; 141(6):2056-2063.e2. PubMed ID: 21856269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.